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Abstract: Mitotane is a steroidogenesis inhibitor and adrenolytic drug used for treatment of
adrenocortical cancer (ACC). Mitotane therapy causes adrenal insufficiency requiring glucocorticoid
replacement in all patients. However, it is unclear whether chronic therapy with mitotane induces
complete destruction of zona fasciculata and whether hypothalamic-pituitary-adrenal (HPA) axis can
recover after treatment cessation. Our objective was to assess the HPA axis recovery in a cohort of
patients after cessation of adjuvant mitotane therapy for ACC. We retrospectively reviewed patient
files with stage I-II-III ACC in two referral centers in Canada and Italy. Data on demographics,
tumor characteristics, hormonal profile, and HPA axis were collected. Data from 23 patients with
pathologically proven ACC treated with adjuvant mitotane for a minimum of two years were analyzed.
Eight patients were males and 15 were females and the median age was 41 years old (range 18 to
73). After mitotane cessation, 18/23 (78.3%) patients achieved a complete HPA axis recovery while
3/23 (13.0%) were unable to tolerate glucocorticoid withdrawal despite having normal hormonal test
values and 2/23 (8.7%) never achieved recovery. The mean time interval between mitotane cessation
and HPA axis recovery was 2.7 years. A high proportion of patients achieved HPA axis recovery
following cessation of mitotane adjuvant therapy. However, complete recovery was often delayed up
to 2.5 years and regular assessment of the hormonal profile is required.
Keywords: adrenocortical carcinoma; mitotane; HPA axis
1. Introduction
Adrenocortical carcinoma (ACC) is a rare but often aggressive tumor with an incidence of one
to two cases per million per year. More than half of cases are diagnosed at an advanced stage and
present with a low five-year disease-free survival [1,2]. In previous studies, adjuvant treatment with
mitotane was shown to increase recurrence-free survival in patients with radically resected ACC [3–5].
Surgically removable tumors of stages I to III presenting with evidence of loco-regional invasion or
aggressive pathologic features such as a high proliferation index (Ki67 > 10%) or a positive margin
status are candidates for this therapy [6–8]. This is highlighted by a recent consensus from the European
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association of endocrinology and European Network for the Study of Adrenal Tumors (ENSAT), which
recommends adjuvant mitotane at therapeutic levels for at least two years in patients operated for
ACC with high recurrence risk [1].
Mitotane is an analogue of dichloro-diphenyl-trichloroethane (DDT) insecticide and has been
used for ACC since the 1960s. It is known to cause frequent side effects including gastro-intestinal
and hepatic disturbances (anorexia, nausea, vomiting and diarrhea, hepatitis, or liver enzyme
elevation), central nervous system toxicity (lethargy, somnolence, dizziness, and vertigo), leukopenia,
increased serum cholesterol, altered drug metabolism, and endocrine disorders such as hypogonadism
and hypothyroidism [9,10]. Mitotane has significant adrenolytic properties, which causes adrenal
insufficiency and, for this reason, an actual standard of care requires that simultaneous replacement with
sufficient glucocorticoid be given to patients receiving mitotane. Less frequently, mineralocorticoid
replacement is also required [1]. In vitro studies showed that mitotane causes interference with
cholesterol metabolism and with mitochondrial activity in adrenocortical cells, which often leads to an
increase in the apoptosis rate. It also reduces adrenal steroidogenesis by inhibiting key mitochondrial
enzymes like CYP11B, which reduces the conversion of hormone precursors into active hormones such
as cortisol [11–14]. It was also found that mitotane could potentially interfere with pituitary function
by comparing adrenocorticotropic hormone (ACTH) levels between patients treated with mitotane
for ACC and patients with primary adrenal insufficiency (autoimmune or post-adrenalectomy) [15].
Basal values and post-CRH stimulation test (100 mcg) both showed a statistically significant decrease
in ACTH levels in patients treated with mitotane, which suggests that this drug might have inhibitory
effects at diverse levels of the hypothalamic-pituitary-adrenal (HPA) axis. Data on whether adjuvant
mitotane causes permanent adrenal insufficiency or recovery of the HPA axis can occur after mitotane
withdrawal remains limited [16]. We present data from two referral centers for ACC patients in Canada
and Italy indicating that the HPA axis recovery can occur in a high proportion of patients several
months after cessation of mitotane therapy.
2. Results
2.1. Patient Profiles
A total of 48 patients with a pathologically proven ACC were identified to have minimally
completed a two-year course of adjuvant mitotane therapy (34 and 14 patients from Italian and
Canadian centers, respectively). Among those, 23 patients (12 from Italy and 11 from Canada) had
sufficient data to interpret the HPA axis recovery status. In this group, all were Caucasians except
for one patient with middle Eastern origin. Eight patients were males and fifteen were females. The
median age was 41 years old (range 18 to 73). Table 1 summarizes data of the studied cohort of patients.
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Table 1. Summarized data of each patient with adrenocortical cancer (ACC) treated with mitotane including tumor characteristics, treatment, and HPA axis evaluation.
ID StudyCenter Sex
Age at
Diagnosis
Hormonal
Secretion
ENSAT
Stage
Tumor
Size
Mitotane
Duration
Mitotane
Peak
Level
Type of
Steroid
Replacement
Maximal Dose
of
Glucocorticoid
Highest
Morning
Cortisol
(8 h)
Morning
ACTH at
Recovery
(8 h)
Maximal
Cortisol
Peak during
ACTH Test
No (Years) (cm) (Months) (mg/mL)
(HC
Equivalent
mg)
(nmol/L) (pmol/L) (nmol/L)
1 Italy F 29 None I 4 24 25.0 CA 60 408 40.3 NA
2 * Italy F 32 NA I 5 25 15.0 CA 40 229 8.8 NA
3 Italy F 55 C II 14 31 17.0 CA 65 339 205.0 NA
4 Italy F 59 C II 10 40 20.0 CA and F 60 373 72.2 NA
5 Italy F 48 NA II 16 43 17.8 CA and F 60 505 13.2 637.3 (a)
6 Italy F 29 A II 13 44 19.0 CA and F 40 337 46.2 350.4 (b)
7 Italy M 27 C II 9 47 20.0 CA 60 486 12.0 NA
8 Italy F 48 C I 3 55 20.0 CA 70 353 23.1 NA
9 Italy F 45 None II 9 56 20.0 HC 25 301 14.1 582.2 (a)
10 Italy M 18 NA II 17 58 28.0 CA and F 50 422 80.3 482.8 (a)
11 * Italy M 54 NA II 11 69 25.0 HC 60 279 120.0 309 (a)
12 Italy F 55 NA II 13 85 24.0 CA 50 475 11.2 NA
13 Canada F 35 C I 5 25 21.1 HC 40 391 8.8 586 (a)
14 Canada M 53 None I 3 33 22.7 HC and F 50 NA NA 594 (a)
15 † Canada F 39 NA II 7 39 25.5 HC 60 NA NA 454 (b)
16 Canada F 21 NA II 7 34 17.6 HC and F 35 122 23.5 605 (a)
17 Canada F 51 None II 13 26 27.1 HC 60 466 3.3 477 (b)
18 Canada M 73 NA III 5 59 11.9 HC 30 374 12.2 538 (b)
19 † Canada F 31 None II 21 33 20.1 HC and F 60 425 71.7 321 (b)
20 Canada M 37 None II 10 25 8.1 HC 45 65 5.8 512 (a)
21 † Canada F 41 A and C III 12 27 20.3 HC 55 310 8.1 NA
22 Canada M 31 NA III 26 25 18.0 NA NA 473 7.9 NA
23 Canada M 62 A and C III 5 29 19.0 HC and F NA 432 2.2 NA
* no HPA axis recovery, †failure at glucocorticoid withdrawal attempt, value corresponding to the highest morning cortisol, M: male, F: female, C: cortisol, A: androgen, ENSAT: European
Network for the Study of Adrenal Tumors, CA: cortisone acetate, HC: hydrocortisone, F: fludrocortisone, NA: not available, ACTH: adrenocorticotropic hormone, a: 250-mcg dose for
ACTH stimulation test, b: 1-mcg dose for ACTH stimulation test.
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Five out of 23 patients (21.7%) were stage I, 14/23 (60.9%) were stage II, and 4/23 (17.4%) were
stage III with a mean ACC size of 10 cm (range 3 to 26 cm). The hormonal secretion profile was
available before the ACC surgical resection in 14 out of 23 patients: 6 were non-secreting, 5 were
producing cortisol only, two had an androgen-cortisol co-secretion, and one was producing androgen
only. Negative margin (R0) was achieved in 14/23 (60.9%) patients and 12 of the tumours had a high
proliferation index (Ki67 > 10%) (range 2 to 67). Surgical laparoscopy was performed in seven patients
that had an ACC size < 8 cm except for one tumour with a size of 11 cm. Surgical laparotomy was
performed for every other tumour (except for two with unknown procedures). Only 1/23 patients had
a metastatic recurrence of ACC eight years after the initial diagnosis.
2.2. Mitotane Exposure
All 23 patients had a 24-month minimal exposure to mitotane therapy with a median duration of
34 months (range from 24 to 85 months). Mitotane therapeutic level duration (mitotane blood level >
14 mg/mL) was shorter than 24 months in 12 patients and could not be determined in three patients
because mitotane blood levels were not available. Mitotane mean maximal blood concentration was
19.4 mg/mL, which range from 8.1 mg/mL to 27.1 mg/mL, with two patients never achieving a maximal
concentration above 14 mg/mL. Maximal daily dose varied from 2 g/day to 4.5 g/day in studied patients.
Only two patients had to discontinue their treatment after 24 and 31 months, respectively, secondary
to side effects.
2.3. Glucocorticoid Supplementation
All patients received a glucocorticoid supplementation with either hydrocortisone (12 patients) or
cortisone acetate (10 patients) during and after mitotane therapy (one patient with unknown treatment).
Mineralocorticoid replacement with fludrocortisone was also necessary for eight patients (34.8%). The
mean maximal daily replacement dose was 69.4 mg (range from 50 to 87.5 mg) for cortisone acetate
and 51.6 mg (range from 25 to 100 mg) for hydrocortisone during mitotane therapy.
2.4. HPA Axis Recovery
A total of 18/23 patients (78.3%) achieved a complete recovery of HPA after mitotane cessation.
Of the five remaining patients, 3/23 (13.0%) achieved a partial recovery with normal laboratory
test values but clinical inability to taper glucocorticoid replacement due to symptoms of adrenal
insufficiency. Lastly, 2/23 patients (8.7%) never achieved recovery of their HPA axis despite having
stopped mitotane therapy for more than two and six years, respectively. The mean interval of time
between the mitotane’s last dose and corticosteroid replacement cessation was 999.6 days (2.7 years)
and the median was 1012 days (2.8 years) (range from 106 to 2991 days) (Figure 1). Eight patients
received simultaneous mineralocorticoid supplementation and fludrocortisone replacement was
stopped at the time of corticosteroid cessation in all except one patient who failed to achieve HPA axis
recovery altogether.
Cancers 2020, 12, 639 5 of 9
Cancers 2020, 12, x FOR PEER REVIEW 5 of 9 
 
 
Figure 1. Schematic representation of mitotane exposure and HPA axis recovery timeline for each patient. 
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Figure 1. Schematic representation of mitotane exposure and HPA axis recovery timeline for each patient.
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3. Discussion
In this cohort of patients with ACC evaluated for HPA axis recovery status after cessation of
mitotane therapy, we found that approximately three out of four patients eventually had a return
of a normal HPA axis. This finding suggests that residual adrenocortical tissue remains viable and
functional despite prolonged exposure to mitotane and its known adrenolytic effect on adrenocortical
cells [11].
Recovery was a very slow process and occurred within a span of several months to many years in
most patients. A possible culprit for this latency was initially suspected to be mitotane’s long half-life
and lipophilic properties that allows it to accumulate in fat tissue [12]. However, this hypothesis is
unlikely, considering that almost every patient had undetectable blood levels of mitotane at the time
of hormonal evaluation, including subjects without HPA axis recovery. Patients with an extended
mitotane exposure (up to 3.5 years) followed a similar evolution course to those with shorter treatment
exposure including those with therapeutic duration of less than two years. In previous studies, there
has been conflicting evidence regarding potential pharmacologic activity of mitotane’s metabolites,
but the most recent data tends to dismiss the relevance of metabolites’ activity in ACC treatment and
monitoring [17–19]. For this reason, metabolites’ measurement is not routinely performed in medical
laboratories and is not expected to have any impact on adrenal function [20].
Other potential variables were explored in search of a cause for the absence or delayed recovery
of HPA axis recovery. Boulate et al. recently demonstrated a potentiating effect of rosuvastatin on
mitotane cell toxicity in vitro [21]. Van Koetsveld et al. showed that mitotane could have an increased
in vitro sensitivity on cortisol-producing ACC tumors [13]. Cusato et al. hypothesized that mitotane
blood levels and dosage could be affected by body fat and seasonal variations in white and brown
adipose tissue [22]. Data revision with attention given to variables such as statin drug use, initial
tumor characteristics (size, hormonal profile, proliferation index), surgery type, and outcome did not
reveal any specific relation with an HPA axis recovery status. We observed, however, that two of the
five patients with absent or partial recovery were the patients with the highest body weight in the
Canadian cohort with 108.9 kg and 130 kg, respectively (third highest was 91.5 kg). Due to the low
number of patients, the body weight impact on HPA axis recovery could be a coincidence in this cohort
and this association needs to be further explored. Five patients in our cohort had Cushing’s syndrome
at presentation with consequent HPA axis suppression. They all achieved a relatively rapid (3.5 to
26 months) and complete HPA axis recovery following mitotane withdrawal with normal or high
ACTH values.
Reduction of pituitary ACTH secretion by mitotane has been described previously as a potential
etiology for HPA axis suppression. Reimondo et al. found that mitotane-treated patients with
adrenal insufficiency had lower ACTH levels than patients with primary adrenal insufficiency of
other etiologies [15]. In our cohort, this finding was also present but not consistent among patients.
An inappropriately low ACTH level was observed in only two of the five patients with abnormal HPA
axis recovery.
In 10 patients, ACTH stimulation testing was not performed and HPA axis recovery was
determined based on a maximal morning cortisol value. In these cases, partial adrenal insufficiency
may not be entirely ruled out [23]. However, none of these patients developed symptoms of adrenal
insufficiency during at least one year follow up after cessation of hydrocortisone replacement.
Overall, follow-up of ACC patients following mitotane cessation was relatively uneventful. At the
time of data analysis, only 1 of the 23 patients presented a metastatic recurrence of ACC eight years
after the initial surgery and was among the two patients unable to stop glucocorticoid replacement
despite having a normal HPA axis recovery with a morning cortisol value of 425 nmol/L. Since no
patient achieved a complete HPA axis recovery and presented signs of recurrent ACC disease, concerns
about a possible lack of mitotane cytotoxic effect on adrenal tumor cells in this setting seems unlikely.
However, the low rate of recurrence could also be explained by the higher prevalence of stage I–II
tumors compared to stage III tumors in this cohort of patients, which naturally presents as a less
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advanced disease and has a better overall survival. In addition, these patients were selected on their
capacity to discontinue adjuvant mitotane after a minimal period of two years after surgery, which
means they were disease-free.
One of the drawbacks of our study is its retrospective design. Despite being reviewed
thoroughly, patient files were sometimes incomplete. This could potentially cause underestimation
or overestimation of some results due to missing data. Another weakness resides in the low number
of patients, which makes it difficult to validate previous hypothesis. Because of this, many findings
presented are exploratory and would need further confirmation in larger cohorts of patients.
This is, to our knowledge, the first study directly addressing the HPA axis recovery in vivo after
mitotane cessation in the patient with ACC. The collaborative nature of this study including data from
a Canadian center and an Italian center was useful given the rarity of ACC.
4. Materials and Methods
Patients’ data was retrieved in a retrospective manner from electronic and paper charts in two
large referral centers: (1) Centre hospitalier de l’Université de Montréal (CHUM), Canada and (2) San
Luigi Hospital, Orbassano, University of Turin, Italy. After obtaining institutional ethical committee
approval from each center, CE2010-304, 09.244 (CHUM), and CE 36/2012 (San Luigi Hospital), every
case from 1992 (Italy) and 1995 (Montreal) to this day with pathologically confirmed ACC of stage
I-II-III based on ENSAT classification [24] was reviewed. Data regarding patient demography, tumour
size, hormonal secretion, type of surgery, duration of adjuvant mitotane therapy, mitotane serum levels,
and corticosteroid replacement was collected and analyzed.
Patients who had completed at least two years of adjuvant mitotane therapy and stopped
the treatment were evaluated for recovery of the HPA axis with a morning cortisol level (before
glucocorticoid supplementation), morning ACTH level (normal range 2.0–11.0 pmol/L in Montreal
and 1.32–13.2 pmol/L in Italy), and 1 or 250 mcg ACTH 1–24 stimulation test if applicable. For the
ACTH stimulation test, patients were asked to stop taking their glucocorticoid supplementation after
the previous morning dose. Cortisol blood levels were measured before intravenous ACTH 1–24
(Cortrosyn, Organon Canada) administration (T0) after 30 min (T30) and 60 min (T60) following the
injection. Mitotane blood concentration was determined by a High-Pressure Liquid Chromatography
method (HPLC) in both centers. Mitotane blood levels were considered therapeutic when a target
of 14–20 mg/mL was reached. Cortisol determinations were performed using a chemiluminescence
immunoassay in both centers (Montreal: ADVIA Centaur, Siemens Healthcare Diagnostics Ltd,
Mississauga, ON, intra and inter-assay CV varying from 3% to 3.8% and 1.9% to 5.5%, respectively, and
Turin: CLIA, Siemens, intra and inter-assay variation coefficient of 3.7–4.2% and 4.4–6.0%, respectively).
Following interpretation of laboratory values, the HPA axis recovery status was determined.
In the Canadian center, reference values for the HPA axis evaluation were considered normal if AM
serum cortisol was above 280 nmol/L or if serum cortisol after ACTH stimulation test reached a peak
level of at least 450 nmol/L. In the Italian center, normal reference values were above 331 nmol/L for an
AM serum cortisol value or above 552 nmol/L for the peak cortisol level during the ACTH stimulation
test. Patients were classified as having either (1) complete HPA axis recovery, (2) normal test values
but inability to withdraw from glucocorticoid supplementation, or (3) insufficient HPA axis recovery.
5. Conclusions
Our results show that 78% of patients treated with adjuvant mitotane therapy after ACC resection
achieve complete HPA axis recovery and are able to discontinue glucocorticoid replacement. This
favorable outcome generally occurs late after mitotane cessation with most patients being glucocorticoid
supplemented for more than two years after the end of mitotane therapy and reaffirms the necessity for
follow-up to determine the need for continuous hormonal replacement in these patients. Unfortunately,
we did not highlight any predictors for HPA axis recovery after mitotane exposure. Further studies are
needed with larger cohorts of patients to give more insights on this clinical challenge.
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